Actively Recruiting

Phase Not Applicable
Age: 50Years +
All Genders
NCT04412187

Inflammatory faCtors AfteR acUte Ischemic Stroke

Led by Martin Dichgans · Updated on 2025-04-04

36

Participants Needed

2

Research Sites

391 weeks

Total Duration

On this page

Sponsors

M

Martin Dichgans

Lead Sponsor

U

Universitätsklinikum Hamburg-Eppendorf

Collaborating Sponsor

AI-Summary

What this Trial Is About

ICARUS is an interventional single-centre hospital-based cohort study in patients admitted to the stroke unit with an acute ischemic stroke. The aims of the study are to i) define the characteristics and determinants of microglial activation after human stroke, and ii) assess the correlation of microglial activation with circulating inflammatory markers, structural brain changes on neuroimaging, and neurological outcomes. ICARUS involves serial TSPO-PET imaging along with serial MRI, immune cell profiling in blood, and both clinical and laboratory assessments in 36 patients with acute ischemic stroke caused by a cortical (N=18) or strictly subcortical (N=18) infarct. In a substudy, the investigators will include 10 independently recruited patients with acute ischemic stroke to assess MRI arterial spin labelling (ASL) sequences as a marker for perfusion measurement of the TSPO tracer.

CONDITIONS

Official Title

Inflammatory faCtors AfteR acUte Ischemic Stroke

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 50 years or older
  • Acute ischemic stroke within 72 hours confirmed by MRI showing a cortical or strictly subcortical infarct
  • Ability to provide written informed consent before participating
  • Willingness to take part in all study assessments including follow-up visits
Not Eligible

You will not qualify if you...

  • Unable or unwilling to provide written consent
  • History of previous stroke, multiple infarcts, or infratentorial infarcts affecting brain stem or cerebellum
  • Known diseases of the central nervous system other than stroke
  • Use of immunomodulatory treatments within 3 months before stroke
  • Chronic inflammatory diseases
  • Infectious diseases within 7 days before stroke
  • Conditions that interfere with follow-up such as end-stage cancer
  • Contraindications for MRI or PET scans (e.g., pacemaker, aneurysm clip, cochlear implant)
  • Radiation exposure exceeding 10 mSv per year
  • Pregnant or breastfeeding women
  • Participation in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Insitute for Stroke and Dementia Research

Munich, Germany, Germany, 81377

Actively Recruiting

2

Department of Nuclear Medicine

Munich, Germany, 81377

Actively Recruiting

Loading map...

Research Team

M

Martin Dichgans, Prof.

CONTACT

A

Anna Kopczak, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Inflammatory faCtors AfteR acUte Ischemic Stroke | DecenTrialz